株式会社極東書店トップ ＞ 商品一覧 ＞ Innovation versus Financialization in the US Pharmaceutical Industry.
商品詳細
Innovation versus Financialization in the US Pharmaceutical Industry.
・ISBN 978-1-009-70799-2 hard GB£ 55.00
￥17,424.- (税込) ※（※）価格はご注文時の参考価格となります。
納品価格につきましては書籍の入荷時点で確定となります。
版元の原価改定、外国為替の変動等により異なる場合がございますので、予めご了承下さい。
お気に入り
★★★
・ISBN 978-1-009-70798-5 paper GB£ 18.00
￥5,702.- (税込) ※（※）価格はご注文時の参考価格となります。
納品価格につきましては書籍の入荷時点で確定となります。
版元の原価改定、外国為替の変動等により異なる場合がございますので、予めご了承下さい。
お気に入り
★★★
電子版あり 大学・学術機関向け電子ブック（eBook）ISBN 978-1-009-70801-2
| 著者・編者 | Tulum, Öner / Lazonic, William, |
|---|---|
| シリーズ | Elements in Corporate Governance |
| 出版社 | (Cambridge U. Pr., UK) |
| 出版年月 | 2025.10 |
| ページ数 | 96 pp. |
| 言語 | ENG |
| ニュース番号 | ＜755-423 755-428＞ |
解説
Mandated by the Inflation Reduction Act of 2022, the US government is negotiating with pharmaceutical companies over the 'maximum fair price' of ten drugs widely used by Medicare patients. The pharmaceutical companies contend that a 'fair' price is a 'value-based price' that enables their shareholders to capture the value the drug creates for society and warn that lowering drug prices will reduce investments in new drugs. This Element responds to these arguments by showing that pharmaceutical companies (a) should have their drug prices regulated, given scale economies in supplying drugs and price inelasticity of drug demand; (b) use their profits from unregulated drug prices to distribute cash dividends and stock buybacks to shareholders; (c) do not typically rely upon investment by shareholders to fund drug innovation; and (d) benefit from 'collective and cumulative learning' in foundational and translational research that is antecedent and external to their investments in clinical research.